{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T02:34:28Z","timestamp":1769740468036,"version":"3.49.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jbspin.2024.105768","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T07:11:59Z","timestamp":1722323519000},"page":"105768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Update on targeted treatments for ANCA-associated vasculitis"],"prefix":"10.1016","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3573-9203","authenticated-orcid":false,"given":"Xavier","family":"Pu\u00e9chal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2024.105768_bib0330","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa0909169","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","volume":"363","author":"Jones","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2024.105768_bib0335","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2024.105768_bib0340","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1002\/art.38044","article-title":"Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis","volume":"65","author":"Miloslavsky","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2024.105768_bib0345","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/annrheumdis-2015-208073","article-title":"Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type","volume":"75","author":"Unizony","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105768_bib0350","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2024.105768_bib0355","doi-asserted-by":"crossref","first-page":"105591","DOI":"10.1016\/j.jbspin.2023.105591","article-title":"Rituximab resistance at 3months of induction therapy in newly diagnosed or relapsing ANCA-associated vasculitis: A French multicentre retrospective study in 116 patients","volume":"90","author":"Machet","year":"2023","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2024.105768_bib0360","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.38788","article-title":"Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. Rituximab in ANCA-Associated Vasculitis-Immune Tolerance Network Research Group","volume":"66","author":"Miloslavsky","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105768_bib0365","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis","volume":"79","author":"Smith","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105768_bib0370","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1002\/art.34583","article-title":"Rituximab for remission maintenance in relapsing ANCA-associated vasculitis","volume":"64","author":"Smith","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2024.105768_bib0375","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1002\/art.38744","article-title":"Rituximab with or without a conventional maintenance agent in the treatment of relapsing granulomatosis with polyangiitis (Wegener's): a retrospective single-center study","volume":"66","author":"Azar","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105768_bib0380","doi-asserted-by":"crossref","first-page":"e2243799","DOI":"10.1001\/jamanetworkopen.2022.43799","article-title":"Rituximab vs cyclophosphamide induction therapy for patients with granulomatosis with polyangiitis","volume":"5","author":"Pu\u00e9chal","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jbspin.2024.105768_bib0385","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2024.105768_bib0390","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/annrheumdis-2017-212768","article-title":"Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides","volume":"77","author":"Terrier","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105768_bib0395","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1136\/annrheumdis-2019-216863","article-title":"Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis","volume":"79","author":"Smith","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105768_bib0400","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/rheumatology\/kez632","article-title":"Rituximab for maintenance of remission in ANCA-associated vasculitis: expert consensus guidelines-Executive summary","volume":"59","author":"Tieu","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105768_bib0405","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","article-title":"Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)","volume":"77","author":"Charles","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105768_bib0410","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard-2023-224489","article-title":"Maintenance of remission of ANCA vasculitis by rituximab based on B cell repopulation versus serological flare: a randomised trial","volume":"83","author":"Zonozi","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105768_bib0415","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1093\/rheumatology\/kez621","article-title":"Reducing the initial number of rituximab maintenance-therapy infusions for ANCA-associated vasculitides: randomised trial post-hoc analysis","volume":"59","author":"Charles","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105768_bib0420","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab use to maintain remission of ANCA-associated vasculitis: A randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2024.105768_bib0425","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1136\/ard-2023-224623","article-title":"Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials","volume":"83","author":"Delestre","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105768_bib0430","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.1093\/rheumatology\/keab916","article-title":"Obinutuzumab as treatment for ANCA-associated vasculitis","volume":"61","author":"Amudala","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jbspin.2024.105768_bib0435","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/art.40802","article-title":"Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized controlled study","volume":"71","author":"Jayne","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105768_bib0440","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2024.105768_bib0445","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/ard-2023-224875","article-title":"CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury","volume":"83","author":"Lodka","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105768_bib0450","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1002\/art.37959","article-title":"Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population","volume":"65","author":"Free","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2024.105768_bib0455","doi-asserted-by":"crossref","first-page":"103266","DOI":"10.1016\/j.jaut.2024.103266","article-title":"Regulatory T cells contribute to downregulation of the autoimmune anti-MPO response","volume":"147","author":"Hu","year":"2024","journal-title":"J Autoimmunity"},{"key":"10.1016\/j.jbspin.2024.105768_bib0460","first-page":"S63","article-title":"Infliximab or rituximab for refractory Wegener's granulomatosis: long-term follow up. A prospective randomised multicentre study on 17 patients","volume":"29","author":"de Menthon","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105768_bib0465","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa041884","article-title":"Etanercept plus standard therapy for Wegener's granulomatosis","volume":"352","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2024.105768_bib0470","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/qjmed\/93.7.433","article-title":"Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity","volume":"93","author":"Jayne","year":"2000","journal-title":"Q J Med"},{"key":"10.1016\/j.jbspin.2024.105768_bib0475","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.23147","article-title":"Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients","volume":"58","author":"Martinez","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2024.105768_bib0480","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1681\/ASN.2007010090","article-title":"Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis","volume":"18","author":"Jayne","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jbspin.2024.105768_bib0485","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2024.105768_bib0490","doi-asserted-by":"crossref","first-page":"e064604","DOI":"10.1136\/bmj-2021-064604","article-title":"The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis","volume":"376","author":"Walsh","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2024.105768_bib0495","doi-asserted-by":"crossref","first-page":"e064597","DOI":"10.1136\/bmj-2021-064597","article-title":"Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline","volume":"376","author":"Zeng","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2024.105768_bib0500","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/ard-2022-223764","article-title":"EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update","volume":"83","author":"Hellmich","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105768_bib0505","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.jbspin.2024.105768_bib0510","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1681\/ASN.2021060771","article-title":"Kidney histopathology can predict kidney function in ANCA-associated vasculitides with acute kidney injury treated with plasma exchanges","volume":"33","author":"Nezam","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jbspin.2024.105768_bib0515","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1016\/0140-6736(93)90759-A","article-title":"Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy","volume":"1","author":"Lockwood","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jbspin.2024.105768_bib0520","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1136\/annrheumdis-2013-204164","article-title":"An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's)","volume":"73","author":"Langford","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105768_bib0525","unstructured":"Langford CA, Khalidi N, Springler J, et al. A randomized, double-blind, placebo-controlled trial of abatacept for the treatment of relapsing, non-severe, granulomatosis with polyangiitis (abstract O-008). 21st International Vasculitis Workshop 2024, 7-10 April 2024."},{"key":"10.1016\/j.jbspin.2024.105768_bib0530","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2024.105768_bib0535","doi-asserted-by":"crossref","first-page":"105472","DOI":"10.1016\/j.jbspin.2022.105472","article-title":"Inhibiting C5a\/C5aR to treat ANCA-associated vasculitides","volume":"90","author":"Terrier","year":"2023","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2024.105768_bib0540","first-page":"1054","article-title":"A randomized, double-blind, phase II study of glucocorticoid replacement by vilobelimab, an anti-C5a monoclonal antibody, in ANCA-associated vasculitis (abstract)","volume":"14","author":"Merkel","year":"2022","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2024.105768_bib0545","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2013.03.003","article-title":"Long-term outcomes of 118 patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome) enrolled in two prospective trials","volume":"43","author":"Samson","year":"2013","journal-title":"J Autoimmun"},{"key":"10.1016\/j.jbspin.2024.105768_bib0550","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/art.40205","article-title":"Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial","volume":"69","author":"Pu\u00e9chal","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105768_bib0555","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.semarthrit.2015.03.004","article-title":"Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: Case report and review of current clinical evidence","volume":"45","author":"Fanouriakis","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2024.105768_bib0560","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2014-206095","article-title":"Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)","volume":"75","author":"Mohammad","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105768_bib0565","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2017-211897","article-title":"Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis","volume":"77","author":"Emmi","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105768_bib0570","doi-asserted-by":"crossref","first-page":"e000905","DOI":"10.1136\/rmdopen-2019-000905","article-title":"Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis","volume":"5","author":"Teixeira","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.jbspin.2024.105768_bib0575","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1136\/ard.2008.093773","article-title":"Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome","volume":"68","author":"Bouldouyre","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105768_bib0580","article-title":"Rituximab versus conventional therapeutic strategy for remission induction in eosinophilic granulomatosis with polyangiitis: A double-blind, randomized, controlled trial (abstract)","volume":"73","author":"Terrier","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105768_bib0585","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2010.03.028","article-title":"Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome","volume":"125","author":"Kim","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jbspin.2024.105768_bib0590","doi-asserted-by":"crossref","first-page":"341","DOI":"10.7326\/0003-4819-155-5-201109060-00026","article-title":"Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome","volume":"155","author":"Moosig","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jbspin.2024.105768_bib0595","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2024.105768_bib0600","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nrrheum.2017.117","article-title":"Vasculitis: Mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"13","author":"Guillevin","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2024.105768_bib0605","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jbspin.2024.105768_bib0610","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2311155","article-title":"Benralizumab versus mepolizumab for eosinophilic granulomatosis with polyangiitis","volume":"390","author":"Wechsler","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2024.105768_bib0615","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard-2023-224624","article-title":"Benralizumab for eosinophilic granulomatosis with polyangiitis","volume":"82","author":"Cottu","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105768_bib0620","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1136\/ard-2023-224756","article-title":"Dupilumab for relapsing or refractory sinonasal and\/or asthma manifestations in eosinophilic granulomatosis with polyangiitis: a European retrospective study","volume":"82","author":"Molina","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2024.105768_bib0625","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejim.2007.09.001","article-title":"Churg Strauss syndrome associated with omalizumab","volume":"19","author":"Pu\u00e9chal","year":"2008","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jbspin.2024.105768_bib0630","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1002\/art.39663","article-title":"Anti-IgE Monoclonal antibody (omalizumab) in refractory and relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Data on seventeen patients","volume":"68","author":"Jachiet","year":"2016","journal-title":"Arthritis Rheumatol"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X24000794?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X24000794?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T11:02:21Z","timestamp":1737630141000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X24000794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1297319X24000794"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2024.105768","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on targeted treatments for ANCA-associated vasculitis","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2024.105768","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author. Published by Elsevier Masson SAS on behalf of Soci\ufffdt\ufffd Fran\ufffdaise de Rhumatologie.","name":"copyright","label":"Copyright"}],"article-number":"105768"}}